Impact of 5-Alpha-Reductase Inhibitors Use at the Time of Prostatic Artery Embolization for Treatment of Benign Prostatic Obstruction

Imagem de Miniatura
Arquivos
art_CARDARELLI-LEITE_Impact_of_5AlphaReductase_Inhibitors_Use_at_the_Time_2019.PDF (328.6 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
Citação
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, v.30, n.2, p.228-232, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: To compare the 12-month post-prostatic artery embolization (PAE) clinical outcomes of patients who were and were not taking 5-alpha-reductase inhibitors (5ARIs) at the time of PAE. Materials and Methods: A retrospective review was conducted of patients who underwent PAE from 2010 to 2017 due to lower urinary tract symptoms, secondary to benign prostatic hyperplasia (BPH). One hundred fifty-five patients were included and divided in 2 groups; these groups did not present statistically significant differences in their baseline characteristics-those taking 5ARIS (Y-5ARIs, n = 40) and those not taking 5ARIs (N-5ARIs, n = 115). International Prostate Symptom Score (IPSS), the sub-item Quality of Life (QoL), and the incidence of clinical failure were used as primary endpoints. Secondary endpoints included mean prostate volume reduction and mean peak flow rate (Q(max)) improvement. Clinical failure or recurrence was defined as absence of symptomatic improvement (IPSS >= 8 or QoL >= 3) or the need for invasive BPH treatment (PAE or transurethral resection of the prostate) during the 12-month follow-up period. Results: After 12-month follow-up, IPSS, QoL, and prostatic volume were significantly lower compared to baseline in both groups, and Q(max) showed a significant increase. No statistically significant differences were observed in outcomes between N-5ARIs and Y-5ARIs, and the clinical failure rate for both groups was approximately 20%. Conclusions: The use of 5ARIs did not show a detrimental effect on clinical outcomes of PAE, in either subjective (IPSS, QoL, and clinical failure) or objective (prostatic volume and Q(max)) parameters.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/31081
Referências
  1. American Urological Association, 2010, MAN BEN PROST HYP
  2. Andriole G, 2004, J UROLOGY, V172, P1399, DOI 10.1097/01.ju.0000139539.94828.29
  3. Bansal A, 2017, J ENDOUROL, V31, P910, DOI 10.1089/end.2016.0696-rev
  4. Burchardt M, 2000, PROSTATE, V43, P184, DOI 10.1002/(SICI)1097-0045(20000515)43:3<184::AID-PROS4>3.0.CO;2-6
  5. Carnevale FC, 2016, CARDIOVASC INTER RAD, V39, P44, DOI 10.1007/s00270-015-1202-4
  6. Carnevale FC, 2013, CARDIOVASC INTER RAD, V36, P1452, DOI 10.1007/s00270-013-0680-5
  7. Carnevale FC, 2017, CARDIOVASC INTER RAD, V40, P366, DOI 10.1007/s00270-017-1569-5
  8. Clark RV, 2004, J CLIN ENDOCR METAB, V89, P2179, DOI 10.1210/jc.2003-030330
  9. de Assis AM, 2015, J VASC INTERV RADIOL, V26, P87, DOI 10.1016/j.jvir.2014.10.012
  10. Gao YA, 2014, RADIOLOGY, V270, P920, DOI 10.1148/radiol.13122803
  11. Goncalves OM, 2016, CARDIOVASC INTER RAD, V39, P1372, DOI 10.1007/s00270-016-1443-x
  12. Gravas S, 2016, EUROPEAN ASS UROLOGY, P1
  13. Hochberg DA, 2002, J UROLOGY, V167, P1731, DOI 10.1016/S0022-5347(05)65188-9
  14. Kurbatov D, 2014, UROLOGY, V84, P400, DOI 10.1016/j.urology.2014.04.028
  15. Lekas E, 2000, BJU INT, V85, P962, DOI 10.1046/j.1464-410x.2000.00671.x
  16. Naslund MJ, 2007, CLIN THER, V29, P17, DOI 10.1016/j.clinthera.2007.01.018
  17. Pareek G, 2003, J UROLOGY, V169, P20, DOI 10.1097/01.ju.0000039923.75777.91
  18. Pisco J, 2013, RADIOLOGY, V266, P668, DOI 10.1148/radiol.12111601
  19. Ray AF, 2018, BJU INT, V122, P270, DOI 10.1111/bju.14249
  20. Rittmaster RS, 1996, J CLIN ENDOCR METAB, V81, P814, DOI 10.1210/jc.81.2.814
  21. Uflacker A, 2016, J VASC INTERV RADIOL, V27, P1686, DOI 10.1016/j.jvir.2016.08.004
  22. Wang MQ, 2016, BJU INT, V117, P155, DOI 10.1111/bju.13147
  23. Worthington-Kirsch Robert L, 2002, Tech Vasc Interv Radiol, V5, P17, DOI 10.1053/tvir.2002.124101
  24. Zhu YP, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0043-4
  25. Zong HT, 2011, ASIAN J ANDROL, V13, P812, DOI 10.1038/aja.2011.86

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/44
Carregar mais